CXCL8 and COVID-19: Previous studies documented that in vitro blockade of PD-1 could almost normalize the immune expression of IL-1β, IL-1RA and IL-8 levels among patients with COVID-19 and restore T cell function, thus recovered the immune abnormalities to normal [50].